DC immunochemotherapy


Protocolnummer:
NL.32381.000.10

Ziekenhuizen:
RadboudUMC Nijmegen

Titel:
Immunochemotherapy: do platin-based chemotherapeutics enhance dendritic cell vaccine efficacy in melanoma patients?

Behandeling:
RNA electroporated dendritic cell product with or without Cisplatin

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: HLA-A2.1 phenotype, melanoma expresing gp100 (compulsory) and tyrosine (non-compulsory, no clinical signs or symptoms of CNS metastases, normal serum LDH, age 18-70. Ex: Prior chemtherapy, immunotherapy or radiotherapy < 4 weeks prior to planned vaccination, serious active infctions, HBsAG or HIV positive or autoimmune diseases or organ allografs, known allergy to shell fish (contains KLH), rapidly progresive disease.

Contactpersoon:
Dr. W van der Graaf

Alle trials